OncoCyte Corporation Relocates Headquarters to Nashville, Rebrands as Insight Molecular Diagnostics
OncoCyte Corporation has relocated its headquarters to Nashville, Tennessee, rebranding as Insight Molecular Diagnostics Inc. (iMDx). This strategic move supports its focus on precision biomarker-based testing in transplant and oncology care. The company's stock will trade under the new symbol "IMDX" on Nasdaq starting June 18, 2025. The laboratory and R&D center will remain in Göttingen, Germany, as the company transitions from product development to commercialization.
OncoCyte Corporation, now known as Insight Molecular Diagnostics Inc. (iMDx), has announced the relocation of its headquarters from Irvine, California, to Nashville, Tennessee. This move aligns with the company’s strategic shift towards precision biomarker-based testing in transplant and oncology care. The company’s stock will trade under the new symbol “IMDX” on Nasdaq starting June 18, 2025. The relocation to Nashville, a hub for healthcare innovation, supports iMDx’s transition from product development to commercialization, while maintaining its laboratory and R&D center in Göttingen, Germany. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OncoCyte Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-015338), on June 17, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
